Drugs
DUSA Pharmaceuticals, Inc., a biopharmaceutical company, has filed a Pre-Market Approval (PMA) Supplement with the FDA for the commercial version of its BLU-U(TM) brand light source. This move follows the FDA's approval of the Company's Levulan(R) Kerastick(TM) 20% topical solution PDT of the
Drugs
The purchase of Cyanamid by BASF for $3.8 billion marks the end of a round of intense consolidation in the agrochemicals sector. Until the Asian-led downturn in global agriculture, investors viewed agrochemicals as a high-value chemical sector, similar to pharmaceuticals. However, with virtually no growth in the $32 billion
Drugs
The European Commission has today launched an investigation into the proposed merger of AstraZeneca, an Anglo-Swedish drugs group, and Novartis, a Swiss life sciences company, in a move aimed at creating the world's first dedicated global agribusiness. The investigation centers on concerns that the joint venture, Syngenta, would
Pharmaceutical industry
Monsanto Co. and Pharmacia & Upjohn Inc.'s merger is proceeding at an accelerated pace, with a projected completion date of April 1, a fortnight ahead of the initially stated second quarter target. The deal still needs shareholder approval, set to be decided on March 23, and European Union
Pharmaceutical industry
ViroPharma Inc. and American Home Products Corp.'s Wyeth-Ayerst Laboratories have initiated human clinical trials for a compound to treat hepatitis C. The trials, conducted at a medical facility in the United Kingdom, aim to evaluate the safety of the compound in healthy human volunteers. This development is a
Drugs
Philip Morris, the nation's largest cigarette maker, has undergone a significant shift in its stance on tobacco regulation. After decades of denials, the company has publicly acknowledged that smoking is addictive and causes cancer and other fatal diseases. This move follows a pattern of growing public pressure and
Pharmaceutical industry
Peter R Dolan, a dynamic leader, has been promoted to president of Bristol-Myers Squibb, responsible for the company's worldwide medicines, beauty care, and nutritional businesses. The appointment is part of a series of personnel changes in the corporation's management team, with John L McGoldrick becoming executive
Pharmaceutical industry
Palatin Technologies, Inc. and Molecular Biosystems, Inc. are moving forward with their corporate growth strategies as they prepare for a merger vote by stockholders. Palatin's LeuTech, a monoclonal antibody for imaging infection sites, has had its Biologics License Application accepted for full review by the FDA. Meanwhile, Molecular
Drugs
SmithKline Beecham's 1999 results surpassed expectations, driven by strong sales of anti-depressant and antibiotic products. The company's 15% rise in earnings per share, exceeding 13% excluding currency effects, underscored its growth momentum. Meanwhile, Glaxo Wellcome's results were marred by slow sales growth and missed
Drugs
The merger of Glaxo Wellcome P.L.C. and SmithKline Beecham P.L.C. created the world's largest pharmaceutical company, Glaxo SmithKline P.L.C. However, the latest earnings report has raised concerns about the success of the merger. Glaxo's earnings rose just 3.8 percent
Drugs
Pfizer's acquisition of Warner-Lambert marks the end of a three-month takeover battle, resulting in the creation of the world's second-largest pharmaceutical company. The combined entity will boast an impressive medicine cabinet, including Viaga and Lipitor, the latter being a blockbuster cholesterol-fighting drug. The deal also sees
Drugs
The European Medicines Evaluation Agency (EMEA) has approved Wyeth-Ayerst Pharmaceuticals' ENBREL (etanercept) for the treatment of active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate, has been inadequate. This approval comes after a positive opinion from the Committee on Proprietary Medicinal Products (CPMP) in
